RecruitingNot ApplicableNCT07110051

Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient

Comparative Study Between Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient


Sponsor

National Cancer Institute, Egypt

Enrollment

128 participants

Start Date

Jan 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

In current study the investigators aim to compare between nalbuphine versus tramadol for post-operative pain control in abdominal surgeries in pediatric.


Eligibility

Min Age: 3 YearsMax Age: 12 Years

Inclusion Criteria3

  • Participants will be children aged 3-12 years
  • American society of anesthesia (ASA) classification I-III.
  • scheduled for elective Abdominal surgery under general anesthesia

Exclusion Criteria3

  • child guardian refusal.
  • Allergy from Tramal or nalbuphine
  • Patient with previous chronic pain on opioids

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNalbuphine

this group will a single dose of nalbuphine (0.2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours)

DRUGTramadol

this group will receive a single dose of tramadol (2 mg/kg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours).


Locations(1)

National cancer institute

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07110051


Related Trials